The Institute for Clinical and Economic Review on Aug. 23 released a draft evidence report on the comparative clinical effectiveness and value of of treatments targeting attacks from hereditary angioedema.
According to a press release, the report is open for public comment until 5 p.m. EST Sept. 20.
The report looks at four therapies:
- Shire’s lanadelumab;
- CSL Behring’s Haegarda;
- Shire’s Cinryze; and
- Pharming’s Ruconest.
The California Technology Assessment Forum is slated to consider the report during its meeting in October.
To read the draft evidence report, click here.